Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$75.00 – $169.90
8% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $65.6M | $62.5M | $60.9M | $65.1M | $102.1M | $92.8M | $266.8M | $104.8M |
| Cost of revenue | $12.4M | $9.2M | $10.4M | $15.1M | $18.8M | $39.3M | $19.9M | $56.1M |
| Gross profit | $53.2M | $53.2M | $50.5M | $49.9M | $83.3M | $53.4M | $246.9M | $48.8M |
| Gross margin | 81.1% | 85.2% | 82.9% | 76.7% | 81.6% | 57.6% | 92.6% | 46.5% |
| R&D | $10.5M | $15.7M | $13.6M | $11.4M | $15.5M | $18.8M | $373.0K | $32.3M |
| Operating income | −$16.6M | −$12.3M | $6.9M | $11.1M | $28.1M | $6.1M | $148.9M | −$10.5M |
| EBITDA | −$12.3M | −$7.0M | $7.8M | $17.8M | $46.7M | $19.7M | $165.7M | $2.4M |
| Net income | −$18.1M | −$24.5M | −$7.9M | $21.7M | $17.2M | −$4.9M | $133.2M | −$3.6M |
| Net margin | -27.5% | -39.2% | -13.0% | 33.3% | 16.9% | -5.3% | 49.9% | -3.5% |
| EPS (diluted) | -1.20 | -1.67 | -0.55 | 1.28 | 1.05 | -0.31 | 8.12 | -0.23 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $103M | $0.10 | $0.07–$0.16 | 1 |
| 2027 | $141M | $2.87 | $2.04–$4.62 | 1 |
| 2028 | $198M | $3.61 | $2.57–$5.81 | 1 |
| 2029 | $283M | $8.33 | $5.92–$13.41 | 1 |
Forward consensus · source: Financial Modeling Prep
COSMO PHARMA NV ORD
No one on the platform currently holds CMOPF.
No tracked institution reports a position in CMOPF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-04-27 | $2.1000 | 2026-05-11 |
| 2025-06-05 | $2.0500 | 2025-06-06 |
| 2024-07-11 | $2.0000 | 2024-07-12 |
No one on the platform has traded CMOPF yet.
| +0.00% |
| $1.1B |
| — |
| LJUIFSSY Group Limited | $0.40 | +0.00% | $1.2B | — |
| NPPNYNippon Shinyaku Co., Ltd. | $6.00 | +0.00% | $1.6B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 7.0× sales vs its 9.6× historical median P/S.
Fair value ≈ $112.94 · price $82.89 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.